2.1
Eptinezumab (VYEPTI, Lundbeck) is indicated for 'the prophylaxis of migraine in adults who have at least 4 migraine days per month'.
2 Information about eptinezumab
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for eptinezumab.
Price
2.3
The price of eptinezumab is £1,350 for a 100 mg per ml vial (excluding VAT; BNF online accessed January 2023).
2.4
The company has a commercial arrangement. This makes eptinezumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.